复锐医疗科技2025年业绩：收入增至3.653亿美元，年内溢利下降13.1%

公告速递

Yesterday

复锐医疗科技于报告期内实现收入3.653亿美元，较上一年度的3.491亿美元增长4.7%。销售成本由1.324亿美元上升至1.502亿美元，毛利从2.167亿美元轻微下降至2.151亿美元，毛利率由62.1%下降至58.9%。年内溢利0.25亿美元，较上一年度的0.288亿美元减少13.1%；经调整纯利0.31亿美元，同比增长7.9%。

除销售成本外，主要成本分项包括销售及分销开支1.295亿美元，行政开支0.362亿美元，研发开支0.169亿美元，融资成本0.032亿美元。报告期末，资产总值为5.51亿美元，上年同期为5.318亿美元；流动资产净值为1.7亿美元，权益总额上升至5.037亿美元。经营活动所得现金净额约0.094亿美元，投资活动所用现金净额约0.017亿美元，融资活动所用现金净额约0.109亿美元，期末现金及银行结余为0.7097亿美元。

分地区来看，北美市场收入约1.11亿美元，亚洲（含中国内地等）约1.474亿美元，欧洲约0.564亿美元，中东及非洲约0.364亿美元，拉丁美洲约0.141亿美元，合计3.653亿美元。董事会建议派发截至二零二五年十二月三十一日止年度末期股息每股0.095港元（含税）。截至报告期末，公司拥有1,047名员工，其中研发员工占比约8.0%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150369501"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150369501\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150369501?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-23 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150369501","market":"us","top_or_hot":-1,"title":"复锐医疗科技2025年业绩：收入增至3.653亿美元，年内溢利下降13.1%","media":"公告速递","content":"<p>复锐医疗科技于报告期内实现收入3.653亿美元，较上一年度的3.491亿美元增长4.7%。销售成本由1.324亿美元上升至1.502亿美元，毛利从2.167亿美元轻微下降至2.151亿美元，毛利率由62.1%下降至58.9%。年内溢利0.25亿美元，较上一年度的0.288亿美元减少13.1%；经调整纯利0.31亿美元，同比增长7.9%。</p>\n<p>除销售成本外，主要成本分项包括销售及分销开支1.295亿美元，行政开支0.362亿美元，研发开支0.169亿美元，融资成本0.032亿美元。报告期末，资产总值为5.51亿美元，上年同期为5.318亿美元；流动资产净值为1.7亿美元，权益总额上升至5.037亿美元。经营活动所得现金净额约0.094亿美元，投资活动所用现金净额约0.017亿美元，融资活动所用现金净额约0.109亿美元，期末现金及银行结余为0.7097亿美元。</p>\n<p>分地区来看，北美市场收入约1.11亿美元，亚洲（含中国内地等）约1.474亿美元，欧洲约0.564亿美元，中东及非洲约0.364亿美元，拉丁美洲约0.141亿美元，合计3.653亿美元。董事会建议派发截至二零二五年十二月三十一日止年度末期股息每股0.095港元（含税）。截至报告期末，公司拥有1,047名员工，其中研发员工占比约8.0%。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复锐医疗科技2025年业绩：收入增至3.653亿美元，年内溢利下降13.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复锐医疗科技2025年业绩：收入增至3.653亿美元，年内溢利下降13.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-03-23 22:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>复锐医疗科技于报告期内实现收入3.653亿美元，较上一年度的3.491亿美元增长4.7%。销售成本由1.324亿美元上升至1.502亿美元，毛利从2.167亿美元轻微下降至2.151亿美元，毛利率由62.1%下降至58.9%。年内溢利0.25亿美元，较上一年度的0.288亿美元减少13.1%；经调整纯利0.31亿美元，同比增长7.9%。</p>\n<p>除销售成本外，主要成本分项包括销售及分销开支1.295亿美元，行政开支0.362亿美元，研发开支0.169亿美元，融资成本0.032亿美元。报告期末，资产总值为5.51亿美元，上年同期为5.318亿美元；流动资产净值为1.7亿美元，权益总额上升至5.037亿美元。经营活动所得现金净额约0.094亿美元，投资活动所用现金净额约0.017亿美元，融资活动所用现金净额约0.109亿美元，期末现金及银行结余为0.7097亿美元。</p>\n<p>分地区来看，北美市场收入约1.11亿美元，亚洲（含中国内地等）约1.474亿美元，欧洲约0.564亿美元，中东及非洲约0.364亿美元，拉丁美洲约0.141亿美元，合计3.653亿美元。董事会建议派发截至二零二五年十二月三十一日止年度末期股息每股0.095港元（含税）。截至报告期末，公司拥有1,047名员工，其中研发员工占比约8.0%。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01696","symbol_name":"复锐医疗科技","start_time":0,"source_url":"","article_id":"1150369501","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150369501","pubTimestamp":1774276125,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"复锐医疗科技于报告期内实现收入3.653亿美元，较上一年度的3.491亿美元增长4.7%。销售成本由1.324亿美元上升至1.502亿美元，毛利从2.167亿美元轻微下降至2.151亿美元，毛利率由62.1%下降至58.9%。年内溢利0.25亿美元，较上一年度的0.288亿美元减少13.1%；经调整纯利0.31亿美元，同比增长7.9%。除销售成本外，主要成本分项包括销售及分销开支1.295亿美元，行政开支0.362亿美元，研发开支0.169亿美元，融资成本0.032亿美元。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01696":"复锐医疗科技"},"translate_title":"Farui MedTech 2025 Results: Revenue Increases to $365.3 Million, Profit Declines 13.1% for the Year","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01696":1},"content_text":"复锐医疗科技于报告期内实现收入3.653亿美元，较上一年度的3.491亿美元增长4.7%。销售成本由1.324亿美元上升至1.502亿美元，毛利从2.167亿美元轻微下降至2.151亿美元，毛利率由62.1%下降至58.9%。年内溢利0.25亿美元，较上一年度的0.288亿美元减少13.1%；经调整纯利0.31亿美元，同比增长7.9%。\n除销售成本外，主要成本分项包括销售及分销开支1.295亿美元，行政开支0.362亿美元，研发开支0.169亿美元，融资成本0.032亿美元。报告期末，资产总值为5.51亿美元，上年同期为5.318亿美元；流动资产净值为1.7亿美元，权益总额上升至5.037亿美元。经营活动所得现金净额约0.094亿美元，投资活动所用现金净额约0.017亿美元，融资活动所用现金净额约0.109亿美元，期末现金及银行结余为0.7097亿美元。\n分地区来看，北美市场收入约1.11亿美元，亚洲（含中国内地等）约1.474亿美元，欧洲约0.564亿美元，中东及非洲约0.364亿美元，拉丁美洲约0.141亿美元，合计3.653亿美元。董事会建议派发截至二零二五年十二月三十一日止年度末期股息每股0.095港元（含税）。截至报告期末，公司拥有1,047名员工，其中研发员工占比约8.0%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}